Moderna, Inc. (MRNA) Quick Ratio
- Quick ratio · latest quarter: Value 2.03×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 2.03× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $5.16B ÷ $2.53B ≈ 2.03× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 5.16B USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 2.53B USD | Liabilities, Current |
| Cash and equivalents | 1.72B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 3.42B USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | 17.00M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 280.00M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.16B | $2.53B | $1.72B | $3.42B | $17.00M | $280.00M | 2.03× |
| 2026-03-31 | $5.28B | $2.40B | $1.91B | $3.30B | $71.00M | $146.00M | 2.20× |
| 2025-12-31 | $5.98B | $1.99B | $2.60B | $3.20B | $184.00M | $153.00M | 3.01× |
| 2025-09-30 | $5.55B | $1.68B | $1.13B | $3.37B | $1.05B | $332.00M | 3.30× |
| 2025-06-30 | $5.17B | $1.57B | $1.28B | $3.85B | $36.00M | $240.00M | 3.29× |
| 2025-03-31 | $6.05B | $1.60B | $1.62B | $4.35B | $78.00M | $128.00M | 3.77× |
| 2024-12-31 | $7.38B | $2.21B | $1.93B | $5.10B | $358.00M | $117.00M | 3.35× |
| 2024-09-30 | $8.43B | $2.20B | $1.64B | $5.22B | $1.56B | $412.00M | 3.83× |
| 2024-06-30 | $8.65B | $2.36B | $2.48B | $6.01B | $163.00M | $399.00M | 3.66× |
| 2024-03-31 | $8.66B | $2.38B | $2.05B | $6.47B | $137.00M | $295.00M | 3.64× |
| 2023-12-31 | $9.50B | $3.02B | $2.91B | $5.70B | $892.00M | $202.00M | 3.15× |
| 2023-09-30 | $9.44B | $4.38B | $2.93B | $4.64B | $1.87B | $487.00M | 2.15× |
| 2023-06-30 | $8.69B | $3.12B | $3.80B | $4.66B | $232.00M | $715.00M | 2.78× |
| 2023-03-31 | $10.04B | $3.50B | $3.44B | $5.48B | $1.11B | $732.00M | 2.87× |
| 2022-12-31 | $11.29B | $4.92B | $3.21B | $6.70B | $1.39B | $949.00M | 2.29× |
| 2022-09-30 | $11.04B | $6.81B | $3.03B | $5.32B | $2.69B | $2.08B | 1.62× |
| 2022-06-30 | $10.59B | $6.81B | $2.87B | $5.02B | $2.69B | $1.92B | 1.55× |
| 2022-03-31 | $13.29B | $9.24B | $5.05B | $5.07B | $3.17B | $1.94B | 1.44× |
| 2021-12-31 | $13.90B | $9.13B | $6.85B | $3.88B | $3.17B | $1.44B | 1.52× |
| 2021-09-30 | $12.05B | $9.96B | $5.55B | $3.36B | $3.14B | $965.00M | 1.21× |
| 2021-06-30 | $10.01B | $8.84B | $5.60B | $2.39B | $2.02B | $643.00M | 1.13× |
| 2021-03-31 | $10.95B | $8.44B | $5.44B | $2.29B | $3.21B | $494.00M | 1.30× |
| 2020-12-31 | $6.00B | $4.39B | $2.62B | $1.98B | $1.39B | $46.53M | 1.37× |
| 2020-09-30 | $3.47B | $1.47B | $1.51B | $1.77B | $190.50M | (m) | 2.35× |
| 2020-06-30 | $2.75B | $161.65M | $1.76B | $955.38M | $33.36M | (m) | 17.01× |
| 2020-03-31 | $1.22B | $134.58M | $391.72M | $825.98M | $5.62M | (m) | 9.09× |
| 2019-12-31 | $1.11B | $143.12M | $235.88M | $867.12M | $5.03M | (m) | 7.74× |
| 2019-09-30 | $1.06B | $147.84M | $173.71M | $884.83M | $2.80M | (m) | 7.18× |
| 2019-06-30 | $1.07B | $161.99M | $151.62M | $918.72M | $3.50M | (m) | 6.63× |
| 2019-03-31 | $1.11B | $159.16M | $502.93M | $605.99M | $5.65M | (m) | 7.00× |
| 2019-01-01 | (m) | (m) | (m) | (m) | $8.95M | (m) | (m) |
| 2018-12-31 | $1.53B | $222.80M | $658.36M | $863.06M | $11.69M | (m) | 6.88× |
| 2018-09-30 | (m) | (m) | $167.06M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | $140.62M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | $90.48M | (m) | (m) | (m) | (m) |
| 2017-12-31 | $767.91M | $191.46M | $134.86M | $621.17M | $11.88M | (m) | 4.01× |
| 2016-12-31 | (m) | (m) | $50.08M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | $159.04M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |